Hanmi Pharmaceutical Company Limited clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   HM15275 · Type 2 Diabetes Mellitus

   Trial sites expanded: 15 → 20 locations

   Hanmi Pharmaceutical Company Limited·Phase 2· NCT07527650· Registry history of NCT07527650 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Minor

   BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic…BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

   Enrollment reduced: 245 → 216 participants

   Hanmi Pharmaceutical Company Limited·Phase 1· NCT06234397· Registry history of NCT06234397 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.